Loading…
Immuron Limited is projected to rise to $1.35 by 2027, a +11% move from its current price of $1.22. IMRN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.16 | $1.22 | $1.29 | +0.14% |
| May 30 | $1.14 | $1.22 | $1.32 | +0.28% |
| May 31 | $1.12 | $1.23 | $1.34 | +0.42% |
| Jun 1 | $1.11 | $1.23 | $1.36 | +0.56% |
| Jun 2 | $1.09 | $1.23 | $1.38 | +0.70% |
| Jun 3 | $1.08 | $1.23 | $1.40 | +0.84% |
| Jun 4 | $1.07 | $1.23 | $1.41 | +0.98% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.07 | $1.23 | $1.41 | +0.98% |
| Week 2 | $1.03 | $1.24 | $1.51 | +1.96% |
| Week 3 | $0.9918 | $1.26 | $1.59 | +2.96% |
| Week 4 | $0.9656 | $1.27 | $1.67 | +3.96% |
| Week 5 | $0.9441 | $1.28 | $1.74 | +4.98% |
| Week 6 | $0.926 | $1.29 | $1.81 | +6.00% |
| Week 7 | $0.9103 | $1.31 | $1.87 | +7.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immuron Limited is a biopharmaceutical company that engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform.
The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Immuron Limited (IMRN) is a healthcare company with a current price of $1.22 and a market capitalization of $9.96M. It ranks 5103 by market cap. The stock trades in a market characterized by a 30-day range of $0.8686 to $1.71, with a current price near a resistance level of $1.22 and a support level of $0.789.
The stock exhibits high volatility, with an annualized volatility of 100% and a neutral near-term sentiment as indicated by a 70 RSI. The price outlook is bullish over the longer horizon, with forecasted average prices increasing from $1.22 in 2026 to a steady ascent toward the 2050 target, while the maximum foreseen prices rise substantially toward the end of the period.
A major floor 47.1% below — a decisive break under it would weaken the trend.
The nearest floor, 35.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 23.6% above — clearing it would confirm fresh momentum.
Key IMRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.04 | Buy | $1.07 | Buy |
| MA 10 | $1.02 | Buy | $1.02 | Buy |
| MA 20 | $0.917 | Buy | $0.9572 | Buy |
| MA 50 | $0.8537 | Buy | $0.8995 | Buy |
| MA 100 | $0.8511 | Buy | $0.9618 | Buy |
| MA 200 | $1.28 | Sell | $1.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.83 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 190.16 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 51.55 | Buy |
| Bollinger %B (20,2) | 1.13 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 82.26 | Sell |
| Momentum (10) | 0.42 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 1.06 | Buy |
| ADX (14) | 17.59 | Neutral |
| ATR (14) | 0.05 | Info |
Near term, the sentiment remains NEUTRAL with an RSI(14) of 70. The 30-day range spans from $0.8686 to $1.71, situating the current price at a resistance level of $1.22. The stock’s short-term moving averages show the SMA50 at $0.8537 and the SMA200 at $1.28, with a nearby support at $0.789.
The chart suggests the price could oscillate around support and resistance in the coming weeks given the elevated volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.70 | $1.22 | $1.72 | 0% | Neutral | |
| $0.9793 | $1.35 | $2.02 | +11% | Neutral | |
| $1.31 | $1.91 | $3.02 | +56% | Bullish | |
| $1.58 | $2.43 | $4.03 | +99% | Bullish | |
| $1.43 | $2.29 | $3.94 | +88% | Bullish | |
| $1.43 | $2.39 | $4.25 | +96% | Bullish | |
| $1.41 | $2.45 | $4.50 | +101% | Bullish | |
| $1.22 | $2.21 | $4.16 | +81% | Bullish | |
| $1.48 | $2.77 | $5.35 | +127% | Bullish | |
| $1.75 | $3.40 | $6.72 | +179% | Bullish | |
| $1.93 | $4.28 | $9.26 | +251% | Bullish | |
| $4.38 | $9.73 | $22.37 | +697% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.70 | $1.22 | $1.44 | +0.00% |
| June 2026 | $1.05 | $1.26 | $1.56 | +3.01% |
| July 2026 | $1.14 | $1.38 | $1.76 | +10.18% |
| August 2026 | $1.13 | $1.39 | $1.80 | +0.49% |
| September 2026 | $1.07 | $1.33 | $1.75 | -4.32% |
| October 2026 | $1.09 | $1.37 | $1.82 | +2.70% |
| November 2026 | $1.09 | $1.38 | $1.86 | +1.00% |
| December 2026 | $0.9837 | $1.26 | $1.72 | -8.82% |
Click any year to see its month-by-month IMRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMRN could reach as high as $1.72, with a base case around $1.22 and support toward $0.70 — roughly 0% from $1.22. A consolidation phase looks the most probable path here.
Expect IMRN to range from $0.9793 to $2.02 through 2027. The $1.35 average target implies a +11% move from current prices. That is up +11% on the projected 2026 average. Price action looks broadly range-bound.
The IMRN price prediction for 2028 points to an average of $1.91 (low $1.31, high $3.02) — a potential gain of +56% on today's $1.22. Buyers look set to stay in control over this stretch.
In 2029, IMRN is projected to trade between $1.58 and $4.03, averaging $2.43 — a potential gain of +99% from today's $1.22. That is up +27% on the projected 2028 average. Momentum favours further upside here.
Immuron Limited's 2030 outlook centres on $2.29, within a $1.43 to $3.94 range. That is -6% versus the projected 2029 average. That marks a +88% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, IMRN could reach as high as $4.25, with a base case around $2.39 and support toward $1.43 — roughly +96% from $1.22. Momentum favours further upside here.
Expect IMRN to range from $1.41 to $4.50 through 2032. The $2.45 average target implies a +101% move from current prices. That is up +3% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The IMRN price prediction for 2033 points to an average of $2.21 (low $1.22, high $4.16) — a potential gain of +81% on today's $1.22. Momentum favours further upside here.
In 2034, IMRN is projected to trade between $1.48 and $5.35, averaging $2.77 — a potential gain of +127% from today's $1.22. That is up +25% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Immuron Limited's 2035 outlook centres on $3.40, within a $1.75 to $6.72 range. That is up +23% on the projected 2034 average. That marks a +179% change versus current levels. Momentum favours further upside here.
By 2040, IMRN could reach as high as $9.26, with a base case around $4.28 and support toward $1.93 — roughly +251% from $1.22. Buyers look set to stay in control over this stretch.
Expect IMRN to range from $4.38 to $22.37 through 2050. The $9.73 average target implies a +697% move from current prices. That is up +127% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IMRN today (≈ 819.672131 IMRN) could be worth
$7,972.02
+$6,972.02 (+697%) by 2050 · US Dollar
Based on the average projected IMRN price of $9.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMRNwould be worth at today's price.
$1,000 invested in IMRN on May 27, 2025 (≈ 518.134729 IMRN) would be worth
$632.12
-$367.88 (-36.8%) today · 0.63× · US Dollar
Based on a IMRN entry price of $1.93 vs. today's $1.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.99 | $1,232.32 | +23.2% |
| 1 month ago | $0.871 | $1,400.69 | +40.1% |
| 3 months ago | $0.84 | $1,452.38 | +45.2% |
| 6 months ago | $1.71 | $713.45 | -28.7% |
| 1 year ago | $1.93 | $632.12 | -36.8% |
| All time (5.0y) ago | $4.85 | $251.55 | -74.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMRN forecast.
Our base-case forecast reaches $2.40 around 2029.
Implied market cap at $2.40: $19.6M
Over the multi-year forecast window, the average price shows a bullish trajectory. The 2026 avg is $1.22, rising in subsequent years to $1.35 (2027), $1.91 (2028), and $2.43 (2029), then $2.29 (2030) and $2.39 (2031), $2.45 (2032), $2.21 (2033), $2.77 (2034), and $3.40 (2035). The outlook strengthens further toward 2040 with an avg of $4.28 and, by 2050, an avg of $9.73.
Foreseeable max prices extend to $22.37 by 2050. Corresponding ROI figures move from 0% in 2026 to 10.8% (2027), 56.3% (2028), 99.1% (2029), 87.5% (2030), 95.6% (2031), 101% (2032), 81.2% (2033), 127% (2034), 179% (2035), 250.8% (2040), and 697.2% (2050). The sentiment remains BULLISH across the later years, with volatility noted at 100%.
These are estimates, not guarantees, and should be considered in the context of inherent investment risk.
Tap a question to reveal the answer.
Avg $2.29, min $1.43, max $3.94; ROI 87.5; sentiment BULLISH.
Yes. The forecast shows neutral in 2026 with avg $1.22, then bullish in 2027-2029 with avg $1.35, $1.91, and $2.43, and continuing to rise to $2.29 by 2030 with ROI 87.5.
2034 max forecast is $5.35; min $1.48; avg $2.77; ROI 127; sentiment BULLISH.
Avg $4.28, min $1.93, max $9.26; ROI 250.8; sentiment BULLISH.
Avg $9.73, min $4.38, max $22.37; ROI 697.2; sentiment BULLISH.
Immuron Limited Community Discussion
0Share your Immuron Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.